A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
Emergent BioSolutions received FDA approval on Feb. 12, 2026, for 6-count and 24-count multipack configurations of over-the-counter NARCAN Nasal Spray, designed to meet the needs of partners distributing higher volumes of naloxone to community programs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07543276 |
Pharmacokinetic (PK) Evaluation of Nalmefene Formulations |
COMPLETED | PHASE1 |
| NCT07485335 |
A Bundled Intervention to End Opioid Overdoses |
NOT_YET_RECRUITING | PHASE4 |
| NCT07079241 |
A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose |
RECRUITING | NA |
| NCT06949605 |
Quantitative Xylazine Measurement in ED |
COMPLETED | |
| NCT06806163 |
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges |
RECRUITING | NA |
| NCT06727786 |
Serious Game to Teach Opioid Overdose Response |
NOT_YET_RECRUITING | PHASE2 |
| NCT06719986 |
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg |
COMPLETED | PHASE1 |
| NCT06593093 |
A Bundled Intervention |
RECRUITING | PHASE1/PHASE2 |
| NCT06527079 |
Evaluation of Clinical Decision Support in Opioid Tapering |
NOT_YET_RECRUITING | |
| NCT06466005 |
UnityPhilly Response App for Overdose Reversal |
RECRUITING |
